ACKR3 and obesity disorder: Moreover, dose-dependent neutralization therapy of one of CXCL12 receptors, CXCR7, blocks CXCR7-mediated AT macrophages chemotaxis and ameliorates insulin resistance and inflammation in obesity [530].